Table 3.
Prevalence of Genotype 6 RAS in Cohort (RAS Definitions From EASL Guidelines 2020 [46])
| Subtype | n | Daclatasvir RAS Detected (n) | Sofosbuvir RAS Detected (n) |
|---|---|---|---|
| 6a | 21 | F/L28V (3); L31M (1) | L159Fb (1) |
| 6e | 14 | F/L28V (7); L28M (5); R30S (14)a; L31I (1); T93S (1) | None detected |
| 6h | 1 | F/L28Va (1) | None detected |
| 6k | 1 | F/L28Va (1) | None detected |
| 6l | 2 | F/L28Va (2) | None detected |
| 6o | 2 | F/L28V (1); T58A (1) T93S (1) | None detected |
Abbreviations: EASL, European Association for the Study of the Liver; RAS, resistance-associated substitutions.
aRAS is considered wild type for this genotype.
bNot considered clinically relevant RAS for genotype 6 but has been shown to be treatment emergent.